The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin

References

• Adson A, Raub TJ, Burton PS, et al. (1994). Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J Pharm Sci 83:1529–36
   PubMed Web of Science ®Google Scholar
• Altenberg GA, Vanoye CG, Horton JK, et al. (1994). Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci USA 91:4654–57
   PubMed Web of Science ®Google Scholar
• Artursson P, Karlsson J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175:880–5
   PubMed Web of Science ®Google Scholar
• Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci 89:429–42
   PubMed Web of Science ®Google Scholar
• Bansal T, Mishra G, Jaggi M, et al. (2009). Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 36:580–90
   PubMed Web of Science ®Google Scholar
• Bromberg L, Alakhov V. (2003). Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 88:11–22
   PubMed Web of Science ®Google Scholar
• Chiou WL, Barve A. (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792–5
   PubMed Web of Science ®Google Scholar
• Choi JS, Piao YJ, Kang KW. (2011). Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34:607–13
   PubMed Web of Science ®Google Scholar
• Choi YH, Kim SG, Lee MG. (2006). Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects. J Pharm Sci 95:2543–52
   PubMed Web of Science ®Google Scholar
• Choubey J, Bajpai AK. (2010). Investigation on magnetically controlled delivery of doxorubicin from superparamagnetic nanocarriers of gelatin crosslinked with genipin. J Mater Sci Mater Med 21:1573–86
   PubMed Web of Science ®Google Scholar
• Cusler EL. (1986). Diffusion: mass transfer in fluid systems. New York: Cambridge University Press
   Google Scholar
• De Mario MD, Ratain MJ. (1999). Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557–667
   Web of Science ®Google Scholar
• Fagerholm U. (2007). Prediction of human pharmacokinetics-gastrointestinal absorption. J Pharm Pharmacol 59:905–16
   PubMed Web of Science ®Google Scholar
• Feng SS, Chien S. (2003). Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 58:4087–114
   Web of Science ®Google Scholar
• Gan LS, Hsyu PH, Pritchard JF, et al. (1993). Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm Res 10:1722–5
   PubMed Web of Science ®Google Scholar
• Garnick MB, Ensminger WD, Israel MA. (1979). A clinical pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res 39:4105–10
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd ed. New York: Marcel Dekker
   Google Scholar
• Gustafson DL, Thamm DH. (2010). Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. J Vet Intern Med 24:579–86
   PubMed Web of Science ®Google Scholar
• Hrishikesh M, Nitya S, Tapobrata L, et al. (2007). A comparative study on the molecular descriptors for predicting drug-likeness of small molecules. Bioinformation 3:384–8
   Google Scholar
• Kakumanu VK, Arora V, Bansal AK. (2006). Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil. Int J Pharm 317:155–60
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Sharma G, Beniwal V, et al. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 26:492–501
   PubMed Web of Science ®Google Scholar
• Ke W, Zhao Y, Huang R, et al. (2008). Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm Sci 97:2208–16
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Kroemer HK, Eichelbaum M. (1995). The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523–30
   PubMed Web of Science ®Google Scholar
• Lee HJ, Chiou WL. (1989). Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm Res 6:833–9
   PubMed Web of Science ®Google Scholar
• Lee HJ, Paik WH, Lee MG. (1995). Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to alloxan-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 89:165–78
   PubMedGoogle Scholar
• Le Lay K, Myon E, Hill S, et al. (2007). Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 8:145–51
   PubMed Web of Science ®Google Scholar
• Lin JH, Chiba M, Baillie TA. (1999). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135–58
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sakaeda T, Ohmoto N, et al. (2002). Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos 30:4–6
   PubMed Web of Science ®Google Scholar
• ONS Clinical Practice Committee (1999). Cancer chemotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society
   Google Scholar
• Pade V, Stavchansky S. (1997). Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 14:1210–5
   PubMed Web of Science ®Google Scholar
• Rushing DA, Raber SR, Rodvold KA, et al. (1994). The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834–41
   PubMed Web of Science ®Google Scholar
• Ryberg M, Nielsen D, Skovsgaard T, et al. (1998). Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502–8
   PubMed Web of Science ®Google Scholar
• Saitoh R, Sugano K, Takata N, et al. (2004). Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res 21:749–55
   PubMed Web of Science ®Google Scholar
• Schellens JH, Malingré MM, Kruijtzer CM, et al. (2000). Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 12:103–10
   PubMed Web of Science ®Google Scholar
• Schwarzbach MH, Eisold S, Burguete T, et al. (2002). Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol 20:1211–8
   PubMed Web of Science ®Google Scholar
• Shen Q, Lin Y, Handa T, et al. (2006). Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 313:49–56
   PubMed Web of Science ®Google Scholar
• Siissalo S, Laitinen L, Koljonen M, et al. (2007). Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm 67:548–54
   PubMed Web of Science ®Google Scholar
• Son HK, Choi JS. (2009). Effects of morin on the bioavailability of doxorubicin for oral delivery in rats. J Kor Pharm Sci 39:243–8
   Google Scholar
• Soucek P, Gut I. (1992). Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica 22:83–103
   PubMed Web of Science ®Google Scholar
• Stephens RH, O‘Neill CA, Warhurst A, et al. (2001). Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 296:584–91
   PubMed Web of Science ®Google Scholar
• Takahashi K, Murakami T, Kamata A, et al. (1994). Pharmacokinetic analysis of the absorption enhancing action of decanoic acid and its derivatives in rats. Pharm Res 11:388–92
   PubMed Web of Science ®Google Scholar
• Troutman MD, Thakker DR. (2003a). Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm Res 20:1192–9
   PubMed Web of Science ®Google Scholar
• Troutman MD, Thakker DR. (2003b). Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 20:1210–24
   PubMed Web of Science ®Google Scholar
• van Asperen J, van Tellingen O, Beijnen JH. (2000). The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28:264–7
   PubMed Web of Science ®Google Scholar
• van Breemen RB, Li Y. (2005). Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 1:175–85
   PubMedGoogle Scholar
• van der Sandt IC, Blom-Roosemalen MC, de Boer AG, et al. (2000). Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 11:207–14
   PubMed Web of Science ®Google Scholar
• van Meer G, Simons K. (1986). The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J 5:1455–64
   PubMed Web of Science ®Google Scholar
• Varma MV, Panchagnula R. (2005). Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. 2005. Eur J Pharm Sci 25:445–53
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Nakai H, Hoshiai H. (2005). The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide. Curr Med Res Opin 21:363–8
   PubMed Web of Science ®Google Scholar
• Wils P, Phung-Ba V, Warnery A, et al. (1994). Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528–30
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Zhao YL, Nadai M, et al. (2006). Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 50:80–7
   PubMed Web of Science ®Google Scholar
• Yoon IS, Choi MK, Kim JS, et al. (2011). Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 41:243–51
   PubMed Web of Science ®Google Scholar
• Yu L, Zeng S. (2007). Transport characteristics of zolmitriptan in a human intestinal epithelial cell line Caco-2. J Pharm Pharmacol 59:655–60
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng SS. (2006). Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27:262–70
   PubMed Web of Science ®Google Scholar